Skip to Content
COVID-19 Resources
Contact DCTD
Show menu
Search this site
Last Updated: 01/27/2017

New NCI Experimental Therapeutics (NExT) Program Heralds Shortened Timeline for Anticancer Drug Development

A new compound, called ABT-888, has passed the first stage of clinical examination using a new model for drug development that promises to shorten -- by up to six to 12 months -- the timeline for taking anticancer drugs from the laboratory to the clinic, according to a team of researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. This result (abstract #3518) was presented June 3, 2007, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. More… External Link

See Also:

New Approaches to Cancer Drug Development and Clinical Trials: Questions and Answers External Link

NCI Experimental Therapeutics Program (NExT)

Dr. Shivaani Kummar’s Phase 0 Presentation at the American Society of Clinical Oncology, June 3, 2007